Dicycloverine hydrochloride with aluminium hydroxide, magnesium oxide and simeticone
Brand names: Kolanticon Gel
This is a compound preparation combining the antimuscarinic antispasmodic dicycloverine hydrochloride with the antacids aluminium hydroxide and magnesium oxide and the antifoaming agent simeticone, used for functional gastrointestinal symptoms with associated dyspepsia and trapped wind.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Dicycloverine relieves gut smooth-muscle spasm via antimuscarinic action, aluminium hydroxide and magnesium oxide neutralise gastric acid, and simeticone reduces gas-bubble surface tension to relieve bloating.
Prescribing in practice
- The dicycloverine component carries antimuscarinic contraindications and cautions (paralytic ileus, obstruction, urinary retention, prostatic enlargement, angle-closure glaucoma) and warrants particular care in older people.
- The antacid components reduce the absorption of several other drugs, so separate the timing of other medicines from this preparation.
- Aluminium and magnesium salts may accumulate or cause bowel-habit changes, and caution is needed in renal impairment.
Monitoring
No routine monitoring is required; review symptom relief and remain alert to antimuscarinic effects and antacid drug interactions.
Counselling the patient
- Take your other medicines at a different time from this preparation, as the antacid can stop them being absorbed properly.
- It may cause a dry mouth or affect your bowels; mention this if troublesome.
- Seek advice if symptoms persist or you develop difficulty passing urine.
Evidence & guidelines
Established prescribing references describe antacid-containing antispasmodic combinations for functional dyspeptic symptoms, with antacids well recognised to reduce absorption of co-administered drugs.
Reference: NICE NG61; NICE NG184; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.